Publicacións en colaboración con investigadores/as de Fred Hutchinson Cancer Research Center (8)

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2019

  1. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Leukemia, Vol. 33, Núm. 1, pp. 159-170

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

  2. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2011

  1. Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2

    Blood

  2. Reply to A. Gratwohl

    Journal of Clinical Oncology

2009

  1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

    Leukemia, Vol. 23, Núm. 10, pp. 1904-1912

2008

  1. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study

    British Journal of Haematology, Vol. 143, Núm. 4, pp. 511-519